Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$41.86 USD

41.86
1,928,753

-0.03 (-0.07%)

Updated Jun 21, 2024 04:00 PM ET

After-Market: $41.88 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Qiagen (QGEN) Up 4.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2

    by Zacks Equity Research

    QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.

      Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates

      by Zacks Equity Research

      Qiagen (QGEN) delivered earnings and revenue surprises of 3.13% and 0.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe

        by Zacks Equity Research

        QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.

          Nabaparna Bhattacharya headshot

          Genomics Market Gains Momentum: 3 DNA Stocks in Focus

          by Nabaparna Bhattacharya

          Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.

            QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth

            by Zacks Equity Research

            QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.

              Why Is QIAGEN (QGEN) Up 13.8% Since Its Last Earnings Report?

              by Zacks Equity Research

              QIAGEN (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff

                by Zacks Equity Research

                QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.

                  QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1

                  by Zacks Equity Research

                  QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.

                    Why QIAGEN (QGEN) Might Surprise This Earnings Season

                    by Zacks Equity Research

                    QIAGEN N.V. (QGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.

                      QIAGEN's QFT-Plus Endorsed for Latent Tuberculosis Screening

                      by Zacks Equity Research

                      QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.

                        QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform

                        by Zacks Equity Research

                        QIAGEN (QGEN) forges ahead with deals to strengthen the GeneReader NGS Platform.

                          5 Reasons Why You Should Add Becton, Dickinson (BDX) Now

                          by Zacks Equity Research

                          Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.

                            BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing

                            by Zacks Equity Research

                            Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.

                              QIAGEN's QFT-Plus Approval in Japan to Expand Customer Base

                              by Zacks Equity Research

                              QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.

                                QIAGEN Strong on Molecular Diagnostics, Competition Rife

                                by Zacks Equity Research

                                QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.

                                  QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View

                                  by Zacks Equity Research

                                  QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.

                                    FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic

                                    by Zacks Equity Research

                                    QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.

                                      QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm

                                      by Zacks Equity Research

                                      QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.

                                        Abbott Boosts Diagnostics Arm With Alinity H-Series Launch

                                        by Zacks Equity Research

                                        Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.

                                          QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

                                          by Zacks Equity Research

                                          QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.

                                            QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View

                                            by Zacks Equity Research

                                            QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.

                                              Should You Sell QIAGEN (QGEN) Before Earnings?

                                              by Zacks Equity Research

                                              QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                                Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

                                                by Zacks Equity Research

                                                Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.

                                                  Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

                                                  by Zacks Equity Research

                                                  Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.